Emmaus Medical Inc.'s pharmaceutical-grade L-glutamine cleared the FDA on its July 7 PDUFA date, becoming the first new treatment for sickle cell disease (SCD) in the U.S. since chemotherapeutic agent hydroxyurea gained approval in 1998, and the first treatment indicated for pediatric patients.